• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Applied Molecular Transport Inc. (Amendment)

    2/11/22 5:05:00 PM ET
    $AMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AMTI alert in real time by email
    SC 13G/A 1 d254894dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    Applied Molecular Transport, Inc.

    (Name of Issuer)

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

    03824M109

    (CUSIP Number)

    December 31, 2021

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☐

    Rule 13d-l(b)

     

      ☐

    Rule 13d-l(c)

     

      ☒

    Rule 13d-l(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

     

     

     


    CUSIP No. 03824M109

     

      1.    

      Names of Reporting Persons

     

      Randall Mrsny, Ph.D.

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

    ☐  (a)          ☒  (b)  

     

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      United States of America

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.     

      Sole Voting Power

     

      44,500 (See Item 4(a) below)

       6.   

      Shared Voting Power

     

      3,600,000 (See Item 4(a) below)

       7.   

      Sole Dispositive Power

     

      44,500 (See Item 4(a) below)

       8.   

      Shared Dispositive Power

     

      3,600,000 (See Item 4(a) below)

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      3,644,500 (See Item 4(a) below)

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      9.46%

    12.  

      Type of Reporting Person (See Instructions)

     

      IN

     

       Page 2 of 5 pages   


    Item 1.

     

      (a)

    Name of Issuer:

    Applied Molecular Transport Inc.

     

      (b)

    Address of Issuer’s Principal Executive Offices:

    1 Tower Place, Suite 850

    South San Francisco, CA 94080

    Item 2.

     

      (a)-(c)

    Name of Person Filing; Address of Principal Business Office or, if none, Residence; Citizenship

    This Statement is filed by Randall Mrsny, Ph.D., c/o Applied Molecular Transport Inc., 1 Tower Place, Suite 850, South San Francisco, CA 94080. Dr. Mrsny is a resident of the United States.

     

      (d)

    Title of Class of Securities:

    Common Stock, $0.0001 par value per share

     

      (e)

    CUSIP Number:

    03824M109

     

    Item 3.

    If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

     

         (a)        ☐      Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
              (b)        ☐      Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
         (c)        ☐      Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
         (d)        ☐      Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
         (e)        ☐      An investment advisor in accordance with §240.13d-1(b)(1)(ii)(E);
         (f)        ☐      An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
         (g)        ☐      A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
         (h)        ☐      A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
         (i)        ☐      A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
         (j)        ☐      A non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J);
         (k)        ☐      Group, in accordance with §240.13d–1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d–
             1(b)(1)(ii)(J), please specify the type of institution:____

     

    Item 4.

    Ownership.

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    (a)

    Amount beneficially owned: 3,644,500 shares which includes (i) 3,600,000 shares held by the Mrsny-Daugherty Living Trust for which Dr. Mrsny serves as co-trustee and exercises voting and investment control, (ii) 3,500 shares held directly by Dr. Mrsny, and (iii) options to purchase an aggregate of 41,000 shares of common stock held by Dr. Mrsny that are exercisable within 60 days of December 31, 2021.

     

    (b)

    Percent of class: 9.46% (percentage ownership is calculated based on 38,489,589 shares of common stock outstanding as of November 3, 2021 as reported on the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 10, 2021, and assumes that the 41,000 shares of common stock underlying the stock options are deemed outstanding pursuant to SEC Rule 13d-3(d)(1)(i)).

     

       Page 3 of 5 pages   


    (c)

    Number of shares as to which the person has:

     

      (i)

    Sole power to vote or to direct the vote:    41,000 shares (See item 4(a) above).

     

      (ii)

    Shared power to vote or to direct the vote:    3,600,000 shares (See item 4(a) above).

     

      (iii)

    Sole power to dispose or to direct the disposition of:    41,000 shares (See item 4(a) above).

     

      (iv)

    Shared power to dispose or to direct the disposition of:    3,600,000 shares (See item 4(a) above).

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    Item 10.

    Certifications.

    Not applicable.

     

       Page 4 of 5 pages   


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    February 11, 2022
    Date
    /s/ Randall Mrsny
    Randall Mrsny

     

       Page 5 of 5 pages   
    Get the next $AMTI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AMTI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AMTI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc.

      Combined company operating as Cyclo Therapeutics with primary focus on advancing Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1) Cash runway extended into 2H 2024 with approximately $11.0 million cash on hand to fund operations Cyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company focused on developing transformative therapies for rare and neurological diseases with limited treatment options, and Applied Molecular Transport Inc. (NASDAQ:AMTI) ("AMT"), a biopharmaceutical company, announced today the closing of its previously announced transaction pursuant to which AMT will merge with Cyclo Therape

      12/27/23 4:15:00 PM ET
      $AMTI
      $CYTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Cyclo Therapeutics Reports Third Quarter 2023 Financial Results

      Strong pace of enrollment continues in pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 ("NPC1") Merger with Applied Molecular Transport, Inc. ("AMT") on track to close before year end Company continues to bolster cash position to extend runway through clinical and regulatory milestones Cyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the third quarter 2023. "Our number one priority remains to

      11/15/23 8:05:00 AM ET
      $AMTI
      $CYTH
      $RFL
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Real Estate
    • Applied Molecular Transport Reports Third Quarter 2023 Financial Results

      Company Entered into Definitive Merger Agreement with Cyclo Therapeutics Cash and Cash Equivalents of $18.1 million, as of September 30, 2023 SOUTH SAN FRANCISCO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT), a biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2023. Recent Business Highlights and Anticipated Milestones Entered into a definitive merger agreement with Cyclo Therapeutics Combined company will operate as Cyclo Therapeutics with primary focus on advancing Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1)The merger is expected to close by year end 20

      11/9/23 4:01:00 PM ET
      $AMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMTI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Epiq Capital Group, Llc disposed of 8,337,518 shares (SEC Form 4)

      4 - Applied Molecular Transport Inc. (0001801777) (Issuer)

      12/29/23 5:40:35 PM ET
      $AMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vandevender Aaron returned 212,659 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Applied Molecular Transport Inc. (0001801777) (Issuer)

      12/28/23 5:39:57 PM ET
      $AMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Smither John W

      4 - Applied Molecular Transport Inc. (0001801777) (Issuer)

      12/28/23 5:38:19 PM ET
      $AMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMTI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • JMP Securities initiated coverage on Applied Molecular with a new price target

      JMP Securities initiated coverage of Applied Molecular with a rating of Outperform and set a new price target of $92.00

      3/17/21 8:25:08 AM ET
      $AMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JMP Securities initiated coverage on Applied Molecular Transport with a new price target

      JMP Securities initiated coverage of Applied Molecular Transport with a rating of Mkt Outperform and set a new price target of $92.00

      3/17/21 7:32:06 AM ET
      $AMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink reiterated coverage on Applied Molecular Transport with a new price target

      SVB Leerink reiterated coverage of Applied Molecular Transport with a rating of Outperform and set a new price target of $74.00 from $32.00 previously

      2/25/21 10:32:42 AM ET
      $AMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMTI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Applied Molecular Transport Inc. (Amendment)

      SC 13G/A - Applied Molecular Transport Inc. (0001801777) (Subject)

      2/14/24 4:24:03 PM ET
      $AMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Applied Molecular Transport Inc. (Amendment)

      SC 13D/A - Applied Molecular Transport Inc. (0001801777) (Subject)

      1/5/24 4:18:22 PM ET
      $AMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Applied Molecular Transport Inc. (Amendment)

      SC 13G/A - Applied Molecular Transport Inc. (0001801777) (Subject)

      2/9/23 4:05:59 PM ET
      $AMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMTI
    SEC Filings

    See more
    • SEC Form 15-12G filed by Applied Molecular Transport Inc.

      15-12G - Applied Molecular Transport Inc. (0001801777) (Filer)

      1/9/24 6:12:27 AM ET
      $AMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Applied Molecular Transport Inc.

      EFFECT - Applied Molecular Transport Inc. (0001801777) (Filer)

      1/3/24 12:15:07 AM ET
      $AMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form POSASR filed by Applied Molecular Transport Inc.

      POSASR - Applied Molecular Transport Inc. (0001801777) (Filer)

      1/2/24 9:15:36 AM ET
      $AMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMTI
    Leadership Updates

    Live Leadership Updates

    See more
    • Applied Molecular Transport Reports First Quarter 2022 Financial Results and Provides Corporate Update

      Announced positive top-line data for AMT-101 FILLMORE Phase 2 trial in chronic pouchitis Independent Data Monitoring Committee (DMC) recommends advancing to Phase 3 Three Phase 2 top-line readouts for oral AMT-101 in ulcerative colitis (UC) and rheumatoid arthritis (RA) anticipated in 2022, consistent with previous guidance SOUTH SAN FRANCISCO, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT), a clinical-stage biopharmaceutical company, today provided a corporate update and reported financial results for the first quarter ended March 31, 2022. "We were pleased to recently announce positive top-line data from our FILLMORE trial in chronic pou

      5/9/22 4:01:00 PM ET
      $AMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Applied Molecular Transport Appoints Charlene Banard to its Board of Directors

      SOUTH SAN FRANCISCO, Calif., April 06, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced the appointment of Charlene Banard to its Board of Directors. Ms. Banard is an accomplished biopharmaceutical executive with over 30 years of experience leading global technical operations and quality organizations within the life sciences industry. Ms. Banard will also become a member of the company's Audit Committee. "Charlene is a welcome addition to AMT's Board of Directors, bringing critical technical operations expertise and a strong strategic vision to the organization," said Tahir Mahmood, Ph.D.,

      4/6/22 8:00:00 AM ET
      $AMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Applied Molecular Transport Appoints Industry Veteran Carolyn Finkle as Senior Vice President, Head of Regulatory Affairs

      Company continues to strengthen key functions and corporate leadership Company on track to announce top-line data from four ongoing oral AMT-101 Phase 2 trials in 2022 SOUTH SAN FRANCISCO, Calif., March 14, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced the appointment of Carolyn Finkle as senior vice president, head of regulatory affairs. She becomes a member of the AMT executive leadership team, reporting to chief executive officer and co-founder of AMT, Tahir Mahmood, Ph.D. "We are thrilled to welcome Carolyn as the newest member of the executive leadership team at AMT," said Dr. Mahmood. "Car

      3/14/22 8:00:00 AM ET
      $AMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMTI
    Financials

    Live finance-specific insights

    See more
    • Applied Molecular Transport Announces Top-line Phase 2 Results from MARKET Combination Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis

      – Similar clinical remission rates observed of 31.8% (7/22) in patients receiving combination (AMT-101 and adalimumab) versus 33.3% (9/27) in patients receiving placebo plus adalimumab at week 8 – Post hoc analysis of patients with shorter duration of ulcerative colitis (UC) < 5 years showed clinical remission rate of 43.8% (7/16) in patients receiving combination versus 15.4% (2/13) in patients receiving adalimumab alone, suggesting combination treatment earlier in the course of disease may be beneficial – AMT-101 appeared safe and well-tolerated – Company will host live conference call and webcast today, July 6, 2022, at 8:30 a.m. ET (5:30 a.m. PT) SOUTH SAN FRANCISCO, Calif., July 06

      7/6/22 8:00:00 AM ET
      $AMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Applied Molecular Transport to Report Top-line Phase 2 Results from MARKET Combination Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis

      SOUTH SAN FRANCISCO, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT) today announced that the company plans to report top-line data results from its Phase 2 MARKET combination trial of AMT-101 (GI- selective, oral fusion of IL-10) with anti-TNFα in biologic-naïve patients with moderate-to-severe ulcerative colitis. The company will issue a premarket press release and host a live webcasted conference call on Wednesday, July 6, 2022, at 8:30 a.m. ET (5:30 a.m. PT). Conference Call & Webcast InformationTo join the conference call via phone and participate in the live Q&A session, please pre-register online here to receive a telephone number and

      7/5/22 4:01:00 PM ET
      $AMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Applied Molecular Transport Announces Positive Top-line Phase 2 Results from FILLMORE Trial of Oral AMT-101 in Patients with Chronic Pouchitis

      –  Met pre-specified efficacy endpoints in chronic pouchitis, a difficult-to-treat inflammatory bowel disease (IBD)–  AMT-101 demonstrated favorable clinical activity and appeared safe and well-tolerated, supporting potentially best-in-class profile–  Achieved clinically meaningful responses in stool frequency and histologic healing in both 3mg and 10mg dosage groups–  Independent Data Monitoring Committee (DMC) recommends advancing to Phase 3 in chronic pouchitis–  Further substantiates potential of AMT-101 and Company's oral biologics platform–  Investor conference call and webcast today at 8:30 a.m. ET (5:30 a.m. PT) SOUTH SAN FRANCISCO, Calif., April 25, 2022 (GLOBE NEWSWIRE) -- Appli

      4/25/22 8:00:00 AM ET
      $AMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care